Ducentis BioTherapeutics

EIS eligible
EQUITY

Company overview

Therapies for inflammation and autoimmune disease

Maturity

Prototyping, preclinical

Sector

Drug Discovery

Market

Inflammation & autoimmune diseases

Goal

£100,000.00

You can indicate your investment interest in this opportunity without any commitment.

Oxford Technology

Lead investor

INFLAMMATION: it can be a real pain in the … !

Inflammation is one of the very basic things our body does to get rid of injured tissue, and when it works properly it’s a great thing. Naturally, there’s a bit of a problem when the inflammatory response goes wild: when you hear “autoimmune inflammatory response”, it essentially means that the body is mistaking its own cells for alien agents and trying to destroy them. Usually it doesn’t just happen as a one off, either, but permanently: your body is under the constant belief that your own nerves, skin cells or hip joints must be destroyed.

This is the cause of many common diseases including Psoriasis or Multiple Sclerosis, and Rheumatoid Arthritis; a condition which causes your own immune system to destroy cartilage and bone with crippling effects.

” Like trying to stop a car using paper brakes. “

  • Click to keep reading (2 min more)

    It has been long known that a particular protein in the body, CD200, reduces the activity of immune response and could potentially be used to treat autoimmune inflammatory responses.

    So could patients simply be treated with natural CD200? In practice, no. This molecule’s natural activity is rather weak, and using it as a medicament would be expensive (synthesising biological molecules isn’t cheap at all). And also… since it is a naturally occurring protein, it cannot be patented. Like it or not, since it can’t be a business no CD200-based treatment has ever been developed.

    Ducentis has modified the structure of the wild-type (naturally occurring( molecule, achieving two very important goals: (1) making it over 50 times more powerful than natural CD200, which would be enough to make this an effective treatment, and (2) modifying it enough so that it CAN be patented, making it a potentially very profitable business – anti-inflammatory drugs for rheumatoid arthritis alone are a $40bn market growing at close to double digits.

    The modified CD200 will now be tested on animals, as well as on human cells. If tests are positive and the program moves into clinical development, then initial clinical testing (referred to as phase II testing by pharma) could be concluded by 2021. If those are positive, according to their projections, then the Ducentis program could be worth £50 to £100M if sold to pharma buyers.

Daniel Oliver

Capital Cell CEO, Biologist and Crowdfunding Expert.
See my LinkedIn
daniel-project

How the company differentiates themselves

HIGHLIGHTS

  • Potential therapeutic targets include transplant rejection and autoimmune and inflammatory diseases.
  • CD200 mutant has 15X greater affinity and 50X greater efficacy than natural-occurring endogenous CD200.
  • CD200 transmits a deactivating signal that attenuates inflammatory responses.
I want to read the investment opportunity sheet

What our experts say  

THIS PROJECT HAS BEEN REVIEWED BY THE BIOEXPERT NETWORK OF 500+ PHD LEVEL SCIENTISTS, PHYSICIANS, IP LAWYERS, CONSULTANTS AND INVESTMENT PROFESSIONALS. THEY HAVE RATED THIS PROJECT BASED ON VARIOUS PARAMETERS, INCLUDING: THE SCIENTIFIC VALIDITY, TEAM EXPERTISE, ROUTE TO MARKET, VALUATION AND INVESTABILITY.

The final ratings  

THESE ARE THE AVERAGE SCORES, TAKEN FROM A VARIETY OF REVIEWS PERFORMED BY THE BIOEXPERT NETWORK AND OUR INTERNAL ANALYTICAL TEAM.

Team

WHAT'S THIS?
THE PROFESSIONAL EXPERTISE OF THE TEAM AND OVERALL STRUCTURE OF THE COMPANY.

Science

WHAT'S THIS?
THE CREDIBILITY OF THE SCIENTIFIC RESEARCH AND DEVELOPMENT, THE STATUS OF THE PATENT AND THE ACCURACY OF THE INFORMATION PRESENTED.

Innovation

WHAT'S THIS?
THE NOVEL MERIT OF THE PROJECT AND COMPARISON OF THE COMPANY TO COMPETITORS.

Business

WHAT'S THIS?
THE MATURITY OF THE COMPANY, AND APPROPRIACY OF THE BUSINESS MODEL, PLAN AND ROUTE TO MARKET.

Financials

WHAT'S THIS?
THE PRESENTATION OF FINANCIAL INFORMATION, INCLUDING PRE-MONEY VALUATION, BALANCE SHEET, FORECAST, EXPECTED ROI, EXIT AND ROI JUSTIFICATION.

Approved by the Bioexpert Network

The BioExpert Network is an independent and exclusive network of industry experts in the sectors of life science and investment. Only proposals which receive the most positive responses, in terms of novel concepts, scientific validity and financial accuracy successfully progress to funding campaign stage on the Capital Cell online platform.

Company Business Plan

Who we are

 

TEAM

Purpose of the project

 

FROM PROBLEM TO SOLUTION

THE PROBLEM

Autoimmune diseases are a major health concern, affecting a significant percentage of the world population and equate to a $50B global market.
Most current biotherapeutic autoimmune therapies indiscriminately block both normal and pathological immune responses. Therefore, more specific solutions are required.

THE SOLUTION

CD200 is an endogenous protein that transmits a de-activating signal to activated immune cells, thus attenuating exaggerated inflammatory responses.

The molecule normally functions to restore a healthy immune system following an inflammatory response. Ducentis believes that administering high affinity CD200 molecules (which are more active than naturally occurring CD200 molecules) will facilitate restoration of a healthy immune system in diseased patients whose exaggerated immune response have overwhelmed the body’s normal restorative processes.

Contact the Company

CONTACT THE COMPANY

Leave a Reply